-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of d ...

Core Viewpoint - CRISPR Therapeutics is positioned for significant growth with the recent approval of its gene therapy, Casgevy, which treats hereditary blood diseases, and is expected to generate substantial revenue in the coming quarters [1][4][5]. Financial Outlook - The company is projected to generate approximately $81 million in revenue for the current year, increasing to $356 million next year, primarily from Casgevy sales [5]. - Analysts do not expect profitability until after 2025, but some anticipate positive earnings per share (EPS) within the next 18 months, indicating potential progress towards profitability [6]. Pipeline and Growth Potential - CRISPR Therapeutics has a promising pipeline, including the CTX211 program for type 1 diabetes, which is in phase 1 trials and could tap into a nearly $39 billion market by 2029 if successful [8]. - Other advanced clinical programs target conditions such as renal cell carcinoma, B-cell malignancies, and atherosclerotic cardiovascular disease (ASCVD), which could further drive growth [9]. Market Position and Investment Considerations - The company's current market capitalization is around $4.8 billion, making it challenging to expect a tenfold increase in value in the near term [10]. - While the stock may not be a "millionaire-maker," it could still provide consistent value to long-term retail investors who are not seeking lottery-style returns [11][12].

These biotech stocks have just launched their first products. The stock market is roaring higher, with the Nasdaq and S&P 500 recently extending gains to reach new record highs. But don't worry. It's not too late to get in on this market growth. The indexes confirmed their presence in a bull market earlier this year, but these phases of market optimism tend to last quite some time -- and history shows us they generally go on for much longer than bear markets. In a study spanning 1926 through 2017, the avera ...

In my view, Vertex and CRISPR Therapeutics are well-positioned to grab upwards of 20% of Casgevy's total addressable market. The therapy -- a one-time treatment that should provide patients with a functional cure -- costs $2.2 million per treatment in the U.S., so there is a multibillion-dollar opportunity here. Casgevy: The sky is the limit Developing gene-editing therapies is difficult, but commercializing them is its own challenge. To administer Casgevy, physicians first need to collect the patient's cel ...

CRISPR Therapeutics AG (NASDAQ:CRSP) BofA Securities 2024 Health Care Conference Call May 15, 2024 12:20 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Meacham All right. Here we go. Okay. Welcome to the second day of the Bank of America Health Care Conference. So my name is Geoff Meacham, I'm the senior biopharma analyst. We are thrilled today to have CRISPR Therapeutics. And speaking on behalf of ...

And that's OK -- at least according to Oppenheimer analyst Jay Olson, who on Friday lowered his price target on CRISPR stock to $95 a share, but maintained an outperform rating on the stock. How much would you pay for a stock that might earn $25 a year in six years? CRISPR Therapeutics (CRSP 2.26%) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 2023, CRISPR's revenue plummeted 99.5% year over ...

These healthcare stocks offer completely different approaches to long-term investment gains. Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon. Moreover, there's a wide variety of healthcare companies, making it an attractive sector for any type of investor. Consider how this value stock and this growth stock below might enhance your portfolio. 1. Pfizer Pfizer (PFE -0 ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this company have returned -15.7%, compared to the Zacks S&P 500 composite's +1.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 0.8%. The key question now is: What could be the stock's fut ...

As investors, we are always aiming to reevaluate our portfolios and make additions. However, we can often get lost in the vastness of the markets when deciding on just a handful of companies. A great place to solve this dilemma is by looking at what other investors are choosing. What better place to start than looking for the best Cathie Wood stocks to buy? After all, she is one of the most famous and respected investors. If she has done the work of rigorously analyzing these companies to put into the holdi ...

CRISPR Therapeutics (CRSP) reported earnings of $1.43 per share in the first quarter of 2024, surpassing the Zacks Consensus Estimate of a loss of $1.63. In the year-ago period, the company had incurred a loss of 67 cents per share.The company’s total revenues, generated entirely from grant revenues, were $0.5 million in the first quarter. The reported figures significantly missed the Zacks Consensus Estimate of $8.3 million. In the year-ago quarter, the company generated revenues worth $100 million, which ...